Ivermectin and Cancer: What Does the Research Say?
Ivermectin has shown anticancer effects in laboratory and animal research, which has made it interesting to cancer researchers. But promising preclinical results are not the same as showing that a treatment helps people live longer or controls cancer in clinical practice.
The short answer
Ivermectin is not currently a proven cancer treatment.
There’s real scientific interest here, as many cell-culture and animal studies have shown anticancer effects. But the key step—proving a meaningful benefit in well-controlled human cancer trials—still hasn’t been taken.
As of August 2026, human trials are investigating ivermectin in oncology, including in combination with immune-checkpoint therapy. That makes ivermectin an experimental cancer strategy, not an established treatment.
What has the research actually found?
Research on ivermectin spans several levels of evidence. The farther down this ladder we move toward controlled human trials, the more directly the evidence can tell us whether a treatment actually helps patients.
Cancer cells in the laboratory
Ivermectin has been to slow growth or cause cell death in various cancer cell lines. Research has looked into its effects on apoptosis, oxidative stress, cell-cycle control, and pathways like Wnt/β-catenin and Akt/mTOR. While intriguing, these findings are still from early-stage cellulture studies.
Animal models
Some experiments have reported reduced tumour growth in animals, including glioblastoma and breast-cancer models. Animal results can justify further study, but they do not establish efficacy or safe cancer dosing in humans.
Case reports and observational data
These studies can suggest hypotheses but can’t reliably prove that ivermectin caused a cancer response. Patients might also be undergoing surgery, radiotherapy, hormone therapy, chemotherapy, immunotherapy, or taking other medications at the same time. A 2026 observational study on ivermectin plus mebendazole is currently under an official Expression of Concern.
Prospective cancer trials
Clinical trials are now examining ivermectin in people with cancer, particularly alongside immune-checkpoint inhibitors. These trials are important because they can define safety, dosing and biological effects — and eventually determine whether cancer outcomes improve.
Practice-changing evidence
There are still no completed large randomized controlled trials showing that ivermectin improves survival, progression-free survival or other definitive cancer outcomes. It is therefore not recommended as a standard cancer treatment.
Why researchers are interested
Ivermectin is already a known antiparasitic medicine, so researchers have extensive pharmacology experience with it at approved doses. Laboratory studies suggest several possible anticancer mechanisms, making it a candidate for drug repurposing.
The concentration problem
A key question in translating research to real-world use is whether the anticancer doses tested in experiments can be safely reached in people. In one cervical cancer lab study, for instance, some toxic effects showed up near the solubility limits, and the remaining growth-inhibiting effects appeared only at levels higher than what’s thought to be achievable in clinical settings.
What human cancer trials are happening?
The human evidence is evolving. Two registered studies illustrate where the field currently stands:
| NCT05318469 Metastatic triple-negative breast cancer |
Phase II ivermectin combined with balstilimab or pembrolizumab (immune-checkpoint therapy). | Recruiting ClinicalTrials.gov record last updated 6 May 2026. |
The trial shows the idea is being tested in people, but the registry does not yet provide completed efficacy results that establish benefit. |
| NCT07487805 — ICONIC Adults with solid tumours receiving checkpoint inhibitors |
A Phase II study of ivermectin with immune-checkpoint inhibition, focusing on safety and immune/pharmacodynamic effects. | Not yet recruiting at last update Record posted 23 March 2026; estimated start July 2026 and estimated enrolment 80. Registry status may lag real-world start dates. |
This is a research study, not evidence that ivermectin is already effective as a cancer treatment. |
Important 2026 evidence updates
Two recent publication notices make it especially important to read ivermectin-cancer claims carefully.
Influential breast-cancer preclinical paper
In 2021, a paper suggested that ivermectin might make “cold” breast tumors more responsive to the immune system and work well with anti-PD-1 therapy. In June 2026, it received an Editorial Expression of Concern, meaning readers should approach it with caution while issues are reviewed. This isn’t the same as a retraction.
2026 ivermectin + mebendazole observational cohort
A study involving 197 patients who self-reported outcomes after being prescribed ivermectin and mebendazole later drew an official Expression of Concern. The journal raised serious doubts about the reliability of the data, the soundness of the statistics, and the adequacy of ethical oversight, prompting a post-publication audit. Since the study was non-randomized and used a drug combination, it cannot prove that ivermectin improved cancer outcomes.
Which cancers have been studied?
Preclinical studies have looked at breast cancer glioblastoma, ovarian cancer, and many other tumor cell lines. Reviews also note possible effects across various signaling pathways and cancer types. Still, the evidence isn’t equally strong for each cancer, and results from a cell line shouldn’t be taken as a treatment recommendation.
A good example is a 2020 study that tested 28 malignant cell lines, finding that several breast and ovarian lines were more sensitive than a prostate line. This shows that even in lab research, different cancers can react in different ways.
What about safety?
Ivermectin has legitimate medical uses. In the UK, oral ivermectin is a prescription-only medicine authorised for specific parasitic infections and scabies. Cancer is not among its authorised indications. Safety experience at approved antiparasitic dosing does not automatically establish the safety of repeated or higher-dose oncology regimens.
Known risks
- Nausea, vomiting, diarrhoea, dizziness and other adverse effects can occur.
- Neurological toxicity can occur with excessive exposure; seizures, altered consciousness and coma have been reported.
- Severe skin reactions, including Stevens–Johnson syndrome and toxic epidermal necrolysis, are listed in current UK product information.
- People having cancer treatment may be particularly vulnerable to drug interactions or overlapping toxicities.
Recent oncology safety reports
In 2026, a case report detailed severe neurotoxicity, including seizures and respiratory failure, following high-dose self-administration in a patient with metastatic breast cancer. Similarly, a 2025 pediatric oncology report described ivermectin toxicity. While case reports can’t measure how common such risks are, they highlight that unsafe dosing and drug interactions can lead to serious consequences.
So, is ivermectin “promising” for cancer?
“Promising enough to study” is a reasonable description. “Proven cancer treatment” is not.
There are some promising mechanisms and encouraging preclinical signs, and researchers are now testing ivermectin in human cancer trials. Still, there are open questions about the right dose, achievable drug levels, possible interactions, which types of cancer might benefit, and whether adding ivermectin truly improves outcomes that matter to patients.
The best way to find answers is through well-designed clinical trials that compare results in people who do and don’t receive ivermectin, using clear tumor measurements, predefined goals, and sufficient follow-up.
Sources & further reading
These links feature clinical trial registries, peer-reviewed articles, and up-to-date medical information. Publication status is important, and any sources with an Expression of Concern are clearly marked above.
- Patel Y, Chawla J, Parmar MS. Ivermectin in Cancer Treatment: Should Healthcare Providers Caution or Explore Its Therapeutic Potential? Current Oncology Reports (2025). Review of preclinical evidence and the clinical evidence gap.
- ClinicalTrials.gov NCT05318469 — Phase II ivermectin with balstilimab or pembrolizumab in metastatic triple-negative breast cancer.
- ClinicalTrials.gov NCT07487805 (ICONIC) — ivermectin combined with immune-checkpoint inhibition in adults with solid tumours.
- Juárez M et al. Antitumor effects of ivermectin at clinically feasible concentrations support its clinical development as a repositioned cancer drug. Preclinical study (2020).
- Liu Y et al. Anthelmintic drug ivermectin inhibits angiogenesis, growth and survival of glioblastoma… Cell and xenograft research (2016).
- Ivermectin-induced cell death of cervical cancer cells in vitro… Study highlighting concentration/solubility limitations in interpreting cell-culture results (2022).
- Editorial Expression of Concern: Ivermectin converts cold tumors hot and synergizes with immune checkpoint blockade for treatment of breast cancer. npj Breast Cancer (2026).
- Expression of Concern regarding the 2026 ivermectin + mebendazole observational cancer cohort. Anticancer Research (2026).
- American Cancer Society: What to Know About Ivermectin (21 May 2026).
- UK electronic Medicines Compendium: Ivermectin 3 mg tablets — Summary of Product Characteristics (current product information).
- Saperstein Y et al. Life-threatening neurotoxicity following off-label ivermectin use in metastatic breast cancer: a case report. Postgraduate Medicine (2026).
Home | Food | Facebook | Other sources | Investors | Editors | Contact